FDA Fast-Tracks Pancreatic Cancer Drug Daraxonrasib

Emerging Hope in Pancreatic Cancer Treatment

The FDA has fast-tracked a new drug for pancreatic cancer, daraxonrasib. Dr. Janette Nesheiwat, a family and emergency medicine physician, discussed its promise on ‘Fox Report.’

Daraxonrasib: A Targeted Approach

This drug is a daily pill aimed at blocking cancer signals associated with the RAS gene. Its early-stage clinical trial was led by the Dana-Farber Cancer Institute and results were published in The New England Journal of Medicine. The trial involved 168 patients with advanced pancreatic cancer and RAS gene mutations, all of whom had received at least one previous chemotherapy treatment.

Clinical Trial Findings

Researchers found that about 30% of participants responded positively to a 300-milligram dose, which is the planned dose for larger phase 3 trials. Additionally, the study showed disease control in approximately 90% of patients as their cancer either reduced in size or stopped progressing. However, side effects like rash, nausea, and diarrhea were noted.

Comments from Experts

“This could change the future of cancer care,” commented Dr. Brian Wolpin, lead investigator and director of the Hale Family Center for Pancreatic Cancer Research.

Wolpin emphasized that daraxonrasib may offer targeted therapy suitable for nearly all advanced pancreatic cancer patients if further trials support the findings. However, the phase 1/2 study does not yet demonstrate clear superiority over chemotherapy.

Future Research Directions

Since the study did not include a randomized control arm comparing daraxonrasib directly with chemotherapy, more research is necessary. Additional studies are needed to explore the potential of daraxonrasib early in the disease progression and to determine optimal treatment sequences.

“Pancreatic cancer remains a challenging disease, and further research is necessary to determine the best treatment combinations and sequences,” Wolpin noted.

Industry Impact

Brian Slomovitz, director of gynecologic oncology at Mount Sinai Medical Center, expressed optimism about the upcoming data presentation at the ASCO meeting. He noted the potential for groundbreaking results should the full dataset support the initial findings. This could reshape treatment strategies and establish daraxonrasib as a new standard of care.

Dr. Slomovitz remarked on the unprecedented potential: “Doubling the survival time in pretreated patients is a significant achievement.” He remains hopeful and optimistic for patients and their families affected by pancreatic cancer.